Organigram Posts Record Q3 Revenue of $105.8M, Sanity Group Drives 49% Growth
OGI sits 50% above its 52-week low of $0.853.
Summary
Organigram reported record Q3 FY2026 revenue of $105.8M (+49% YoY) and adjusted EBITDA of $13.4M, driven by the Sanity Group acquisition. Net income of $105.5M was largely non-cash. A material weakness in internal controls persists.
Key Events · Earnings and Guidance · OGI
-
Record Quarterly Revenue
Net revenue reached $105.8 million, up 49% year-over-year, driven by the first full quarter of Sanity Group's contribution (~C$40 million) and improved Canadian recreational sales.
-
Adjusted EBITDA More Than Doubles
Adjusted EBITDA rose 136% to $13.4 million, reflecting higher international sales and improved operating efficiencies domestically.
-
Net Income Boosted by Non-Cash Gain
Net income of $105.5 million included a $105.8 million non-cash fair value gain on preferred shares, primarily due to a shorter estimated period until BAT reaches the 49% ownership threshold.
-
Material Weakness in Internal Controls
Management concluded that ICFR was not effective as of June 30, 2026, due to a material weakness related to complex spreadsheets used in biological assets and inventory valuation. Disclosure controls were also not effective.
Analysis · OGI · Life Sciences
Organigram delivered its strongest quarter ever, with net revenue surging 49% to $105.8 million, powered by the first full quarter of contributions from the recently acquired Sanity Group. Adjusted EBITDA more than doubled to $13.4 million, and the company reiterated its full-year revenue target of over $350 million. However, the quarter's $105.5 million net income was overwhelmingly driven by a non-cash fair value gain on preferred shares — not operational earnings. The company also disclosed that a material weakness in internal controls over financial reporting remains unremediated, and its disclosure controls are not effective. While the top-line growth and international expansion are clear positives, the control deficiencies and reliance on non-cash gains temper the headline numbers.
At the time of this filing, OGI was trading at $1.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $143.3M. The 52-week trading range was $0.85 to $2.24. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.